What Are Fingolimod and Natalizumab?

Fingolimod (marketed as Gilenya) and Natalizumab (marketed as Tysabri) are both disease-modifying therapies (DMTs) used in the treatment of relapsing forms of multiple sclerosis (MS). While they share the same therapeutic goal of reducing MS disease activity, they work through entirely different mechanisms.

Fingolimod functions by trapping immune cells in lymph nodes, preventing them from entering the central nervous system where they could cause damage. It's typically taken as a once-daily oral capsule, making it convenient for many patients. Natalizumab, on the other hand, works by blocking the movement of potentially harmful immune cells from the bloodstream into the brain and spinal cord. It's administered as an intravenous infusion every four weeks, requiring regular clinic visits.

Why Consider Switching Treatments?

The decision to switch from Fingolimod to Natalizumab is typically made for several reasons. The most common is inadequate response to Fingolimod, where patients continue to experience relapses or show new lesions on MRI scans despite treatment. Other reasons include intolerable side effects from Fingolimod or safety concerns that emerge during treatment.

Some patients may switch due to convenience factors as well. While Fingolimod requires daily dosing, Natalizumab's monthly infusion schedule might better suit certain lifestyles. Medical professionals assess each patient's disease activity, treatment history, risk factors, and personal preferences before recommending a treatment change.

It's important to note that switching MS medications is a significant medical decision that should never be made without thorough consultation with a neurologist specializing in MS treatment.

The Transition Process

The transition from Fingolimod to Natalizumab requires careful planning due to the unique pharmacological properties of these medications. Fingolimod has a long half-life, meaning it stays in the body for an extended period after discontinuation. This necessitates a washout period before starting Natalizumab.

Typically, neurologists recommend a washout period of 2-6 weeks after stopping Fingolimod before initiating Natalizumab treatment. This timeframe allows for the elimination of Fingolimod from the system and the normalization of lymphocyte counts, which are suppressed during Fingolimod treatment.

During this transition period, patients should be closely monitored as they may experience increased disease activity. Some physicians may recommend bridging therapies, such as corticosteroids, to manage potential MS symptoms during the washout period. The exact protocol will vary based on individual patient factors and the neurologist's assessment.

Treatment Comparison and Provider Information

When considering the switch between these treatments, understanding how they compare is essential:

  • Administration: Fingolimod is an oral daily pill, while Natalizumab requires monthly infusions at a healthcare facility
  • Monitoring: Both require regular monitoring, but Natalizumab requires more intensive screening
  • Efficacy: Both are highly effective, with studies showing comparable relapse reduction rates
  • Side Effect Profiles: They have different safety concerns that must be weighed individually

The manufacturers of these medications provide comprehensive support programs for patients:

Novartis, the maker of Gilenya (Fingolimod), offers the Gilenya Go Program that provides financial assistance and nurse support to eligible patients.

Biogen, the manufacturer of Tysabri (Natalizumab), provides the Tysabri Touch program, which includes comprehensive support services and required safety monitoring.

The National MS Society offers resources to help patients navigate treatment decisions and provides information about available support programs.

Benefits and Considerations of Switching

Switching to Natalizumab may offer several potential benefits for patients who haven't responded well to Fingolimod. Studies have shown that Natalizumab can be highly effective at reducing relapse rates and preventing new MRI lesions, even in patients who have had breakthrough disease activity on other therapies.

However, there are important considerations to weigh before making the switch:

The most significant risk associated with Natalizumab is Progressive Multifocal Leukoencephalopathy (PML), a rare but serious brain infection. Prior to starting Natalizumab, patients must be tested for JC virus antibodies, as those who test positive have an increased risk of developing PML. Regular antibody testing continues throughout treatment.

The monthly infusion requirement for Natalizumab means more frequent healthcare visits compared to Fingolimod's at-home administration. This may impact work schedules and require travel planning. Additionally, some patients may experience infusion reactions, though these are typically mild and manageable.

Insurance coverage and out-of-pocket costs may differ between these medications. The Multiple Sclerosis Coalition provides resources to help patients navigate insurance issues related to MS treatments.

Conclusion

Transitioning from Fingolimod to Natalizumab represents a significant treatment decision that should be made collaboratively between patients and their healthcare providers. While the switch may offer improved disease control for some patients, it requires careful planning and ongoing monitoring. The washout period between medications is particularly important to manage safely.

For optimal results, patients should maintain open communication with their neurologist throughout the transition process, report any new or worsening symptoms promptly, and adhere strictly to the recommended monitoring schedule. With proper medical supervision, many patients successfully transition between these medications and experience good outcomes in their MS management.

Remember that treatment decisions are highly individualized. What works well for one person may not be ideal for another. Working closely with healthcare providers who specialize in MS care ensures that treatment decisions are tailored to each patient's unique disease characteristics, risk factors, and personal preferences.

Citations

This content was written by AI and reviewed by a human for quality and compliance.